Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.58 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230157 | 0.83 | POLB (0.84) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL8322003 | 0.83 | POLB (0.66) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL9302629 | 0.83 | POLB (0.66) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL5952740 | 0.82 | DDAH1 (0.59) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL6244548 | 0.80 | POLB (0.72) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL4716249 | 0.80 | POLB (0.66) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL7854448 | 0.80 | POLB (0.92) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL7006523 | 0.80 | POLB (1.00) | POLBNPC1RAB9ACHRM1PDE10A | |
| SCHEMBL23073637 | 0.79 | PDE10A (0.66) | POLBNPC1RAB9APDE10AKDM4E | |
| SCHEMBL9113349 | 0.79 | POLB (0.60) | POLBNPC1RAB9ACHRM1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3509627-A1 | LYSINE SPECIFIC HISTONE DEMETHYLASE-1 INHIBITORS AND USES THEREFOR | University of Canberra (AU) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018045422-A1 | LYSINE SPECIFIC HISTONE DEMETHYLASE-1 INHIBITORS AND USES THEREFOR | UNIVERSITY OF CANBERRA (AU) | 2018-03-15 | — | — | WO | disclosed |
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2051962-B1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-2051962-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-04-29 | — | — | EP | disclosed |
| CN-101410367-A | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | UNIV WAYNE STATE (US) | 2009-04-15 | — | — | CN | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008017989-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-14 | — | — | WO | disclosed |
| CN-1059445-C | Novel derivatives of erythromycin, their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 2000-12-13 | — | — | CN | disclosed |
| CN-1126997-A | Novel erythromycin derivatives, method for preparing same and use thereof as drugs | ROUSSEL UCLAF (FR) | 1996-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | POLB 1149/4885NPC1 2736/4885RAB9A 61/4885 |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | POLB 4027/4885NPC1 2931/4885RAB9A 910/4885 |
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | HCRTR1, HCRTR2, NPSR1 | POLB 4060/4885NPC1 1512/4885RAB9A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.